Perturba Therapeutics a oncology focused spin out from the University of Toronto advancing a pipeline of assets from undrugged protein-protein interactions (PPIs).

Founded in 2021 as a venture between AI drug discovery company Cyclica and the Stagljar Lab at the University of Toronto, Perturba integrates Cyclica’s AI-augmented drug discovery platform with sensitive live cell-based technologies for studying protein-protein interactions and identifying novel drug molecules from the Stagljar lab.

The company is developing precision therapies that modulate PPIs and PPI-mediated biological processes with a focus on difficult-to-treat cancers. Perturba will initially focus on advancing two EGFR triple mutant inhibitors for non-small cell lung cancer, and four programs targeting small GTPases for various intractable cancers.

Perturba says that Cyclica will provide initial funding for Perturba and will seek external funding from strategic partners as required.

Subscribe for alerts on new companies featured on Startups.Bio